CompletedNot Applicable

Role of Beta-blockers in the Prevention on the Arisen of a Severe Sepsis (TESS)

France2,444 participantsStarted 2009-09

Plain-language summary

The severe sepsis (SS) and toxic shock (TS) are both frequent and severe complications of infectious diseases. They are one of the top ten causes of death in industrialized countries. But an eventual protective role of beta-blockers (anti-hypertensive drug) in their occurrence on a community infection has never been studied. The objective of this study is to evaluate this role.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Common characteristics of cases and controls: * Patients aged of more than 18 years old * Hospitalized patients, during the period of study, via the ICU of the participating hospital center, for a community infectious pathology: * lower respiratory infections (pneumonia) * intra-abdominal infections (cholangitis, diverticulitis, peritonitis) * urinary parenchymal infection (pyelonephritis complicated or without abscess, prostatitis, orchitis, epididymitis) * infections of skin and soft tissue infections (cellulitis, fasciitis) * meningitis, endocarditis, osteo-articular infections, salpingitis Definition of cases: * Patient included in the study and admitted to the emergency service either directly from ICU or after a hospitalization in a specialty for severe sepsis or septic shock on their infectious disease community. Definition of controls: * Patient included in the study with an infectious disease community, admitted to a specialty, and have not progressed to severe sepsis or septic shock before being released from the hospital. Non inclusion Criteria: * Opposition of the patient to the IT processing of its data within the framework of this observational study. * Exclusion criteria: Occurrence, during hospitalization, a severe sepsis or septic shock associated with a nosocomial superinfection.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The primary outcome is the occurrence of severe sepsis, moving toward or away from septic shock.

Timeframe: Participants will be followed for the duration of hospital stay, an expected average of 4 weeks

Trial details

NCT IDNCT01606631

SponsorRennes University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2012-02

View on ClinicalTrials.gov More Community-Acquired Infections trials